Biocon
Anil S. has an extensive work experience in the pharmaceutical industry. Anil started their career at Ranbaxy in 1994 as a Senior Scientist in the Drug Regulatory Affairs department. Anil then worked at Orchid as a Manager in Regulatory Affairs from 2001 to 2002. Anil then joined Ranbaxy (Guangzhou China) Ltd. in Beijing, China, where they served as the Head of Regulatory Affairs and Clinical Research from 2002 to 2005. Following this, they worked at Jubilant Organosys Ltd as the Head of Regulatory Affairs, focusing on filing and approvals in the USA and Europe from 2005 to 2006. Anil then joined Cadista Pharmaceuticals Inc. as the Director of Regulatory Filings from 2007 to 2009. Anil later joined Strides Inc. as the Director of Regulatory Affairs for North America from 2009 to 2012, and was then promoted to Assistant Vice President from 2012 to 2013. Anil then worked at Mylan Inc. as the Senior Director of Regulatory Affairs from 2013 to 2018. Anil'snext role was at Teva Pharmaceuticals, where they served as the Senior Director of Gx Steriles from 2018 to 2020. Currently, Anil serves as the Vice President and Global Head of Regulatory Affairs at Biocon, starting in 2020.
Anil S. attended Jamia Hamdard from 1992 to 1994 and obtained a M.Pharm degree in Pharmaceuticals.
This person is not in any teams
This person is not in any offices
Biocon
22 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.